SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on July 13, 2005. The filing discloses the closing of a private placement of equity securities and the corresponding amendment to the Company's Articles of Incorporation to authorize the issuance of Series A Convertible Preferred Stock.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $2,771,000 raised from the sale of 277,100 shares of Series A Convertible Preferred Stock and 386,651 warrants.
- Transaction Costs: The Company paid $277,100 in cash and issued 105,432 warrants to selling agents.
- Warrant Terms: Warrants issued to investors and agents are immediately exercisable at $3.25 per share with a five-year expiration.
- Preferred Stock Terms:
- Stated Value: $10 per share.
- Dividends: Cumulative at 4% per annum, payable quarterly starting September 30, 2005. Dividends may be paid in cash or common stock (valued at 90% of the 20-day VWAP) if funds are legally available.
- Conversion Price: $2.15 per share (at the option of the holder).
- Liquidation Preference: Senior to common stock, entitled to stated value plus accrued dividends.
Note: This filing does not provide revenue, profit, cash flow, or margin data for the Company's operations.
Material Changes and Covenants
The Company entered into a Securities Purchase Agreement and amended its Articles of Incorporation. Key covenants include:
- Participation Rights: Investors have the right to participate in subsequent financings up to $2,771,000 until January 9, 2006.
- Registration Rights: The Company agreed to file a registration statement within 30 days of closing to cover the resale of underlying common stock.
- Lock-up/Restrictions: The Company agreed not to offer securities for sale prior to the effectiveness of the registration statement and not to file a new registration statement for additional shares for 180 days thereafter.
- Anti-Dilution: The conversion price is subject to adjustment (full ratchet) if the Company issues common stock or equivalents at a price lower than the conversion price.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on future business outlook or specific operational risks. However, the transaction structure introduces the following contingencies:
- Liquidity Risk: The Company's ability to pay dividends in cash depends on legally available funds; otherwise, dividends accrue or are paid in stock (subject to registration).
- Dilution Risk: The full ratchet anti-dilution provision could significantly reduce the conversion price if future equity is sold at a discount, increasing potential dilution to common shareholders.
- Automatic Conversion: The Company may force conversion of preferred stock to common stock if the common stock trades at or above $4.30 for 20 consecutive days (subject to volume requirements) after July 13, 2006.
Key Facts for Investor Verification
- Verify the effectiveness date of the Registration Statement filed to cover the resale of the preferred stock and warrants.
- Monitor the Company's cash position to determine if quarterly dividends will be paid in cash or common stock.
- Track future equity issuances to assess potential triggers for the full ratchet anti-dilution adjustment on the conversion price.
- Confirm the number of shares outstanding post-conversion if the automatic conversion trigger ($4.30 VWAP) is met.